Bristol-Myers Squibb (BMS) has reported positive results from its Phase III clinical trial (CheckMate -214) of Opdivo and Yervoy combination for renal cell carcinoma (RCC).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The trial has been stopped early upon recommendation from an independent Data Monitoring Committee (DMC), as it has met the co-primary endpoint of superior overall survival (OS) when compared to current standard-of-care sunitinib in intermediate and poor-risk patients.

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor developed to leverage the body’s immune system to aid restoration of anti-tumour immune response, while Yervoy is a monoclonal antibody that stimulates the immune system by targeting CTLA-4 protein receptor.

The randomised, open-label Phase III CheckMate -214 trial included patients with previously untreated advanced or metastatic RCC.

Subjects were administered with four doses of 3mg/kg of Opdivo in combination with 1mg/kg of Yervoy every three weeks, followed by 3mg/kg of Opdivo every two weeks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sunitinib was given as a 50mg once-daily dose for four weeks, followed by two weeks off period before treatment continuation.

The trial’s primary endpoints are progression-free survival (PFS), OS and objective response rate (ORR) in intermediate to poor-risk patients, while the secondary endpoint is safety.

"The company looks forward to sharing the full results with regulatory authorities and will incorporate this data into the planned European Society for Medical Oncology (ESMO) Congress presentation later this week."

Bristol-Myers Squibb new asset development head Vicki Goodman said: “This overall survival result from CheckMate -214 highlights the potential of the combination of Opdivo and Yervoy to provide a new treatment option for first-line advanced renal cell carcinoma patients for whom there is a considerable unmet need.

“The company looks forward to sharing the full results with regulatory authorities and will incorporate this data into the planned European Society for Medical Oncology (ESMO) Congress presentation later this week.”

It is reported that the combination therapy has also met the secondary endpoint of improved OS compared to sunitinib in all participants.

The safety and tolerability of the combination observed during the CheckMate -214 trial was found to be consistent with existing data from the same dosing schedule and similar across subgroups.

Image: Micrograph of a renal cell carcinoma. Photo: courtesy of Nephron.